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p53 is a transcriptional activator and repressor, but
recent evidence suggests that some of its many bio-
logical functions may not be dependent on transcrip-
tion. To determine whether p53 exerts a direct influence
on nuclear DNA replication, purified human p53 was
added to a transcription-free DNA replication extract
from Xenopus eggs. Full-length human p53 that inhibits
SV40DNA replication in vitro had no effect on nuclear
DNA synthesis in the Xenopus system. In contrast, a
C-terminal truncated form of p53 (p53A30), which is
constitutively active for DNA binding and similar to
an alternately spliced form found in vivo, showed a
concentration-dependent inhibition of DNA replication
in both the soluble SV40 system and eukaryotic nuclei.
This inhibition occured primarily at initiation of DNA
synthesis. Oxidation of p53A30, which eliminates DNA
binding activity, also abrogated the protein's ability to
inhibit nuclear DNA synthesis. The p53 binding DNA
consensus sequence enhanced rather than competed
away inhibitory activity of p53A30. Therefore, p53 that
is constitutively active for DNA binding can inhibit
nuclear DNA replication in the absence of transcrip-
tion. This inhibition may require binding of p53 to
DNA, in addition to interactions between p53 and
proteins of the replication complex.
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Introduction
p53 is a tumour suppressor protein that is important
in maintaining genomic integrity. The protein has been
postulated to act as a 'guardian of the genome' (Lane,
1992), monitoring the state of the cell's DNA. p53
normally has a short half-life and is present in undetectably
low amounts in normally dividing cells, but it is induced
to high levels on DNA damage, resulting in arrest of cell
growth and division (Kasten et al., 1991, 1992; Lu and
Lane, 1993). The importance of p53 in this context can
be inferred from the observation that loss or mutation of
p53 is found in more than half of all human tumours
(Mulligan et al., 1990; Nigro et al., 1989). The high levels
of p53 induced in response to DNA damage correlate with
arrest at the GI stage of the cell cycle (Kasten et al., 1992)
and this has generally been attributed to the transcriptional
activity of p53 (Fields and Yang, 1990). The hypothesis
of an indirect transcriptional effect of p53 on the cell
cycle has been strengthened by recent reports that p53
transcriptionally induces a protein p21/WAF- 1 that inhibits
the activity of the cell cycle regulatory cyclin-dependent
kinases in GI (El-Deiry et al., 1993; Gu et al., 1993;
Harper et al., 1993; Serrano et al., 1993; Xiong et al.,
1993). Additionally, p21 has been found to bind to PCNA,
the DNA polymerase 6 auxiliary factor, and p21 itself can
prevent synthesis of SV40 DNA in vitro, presumably via
this interaction (Flores-Rozas et al., 1994; Waga et al.,
1994; Warbrick et al., 1995).
However, various lines of evidence suggest that p53
can also act to suppress growth by non-transcriptional
mechanisms. Some mutant p53 proteins that have lost
transcriptional transactivation capacity retain their ability
to arrest cell growth to varying extents (Zhang et al.,
1993a,b; C.A.Midgley, unpublished results). The domains
of p53 involved in transcriptional activation (N-terminal)
may differ from those required for transcriptional repres-
sion (C-terminal) (Sang et al., 1994; Subler et al., 1994),
suggesting that these two phenomena are separable and
that growth arrest or tumour suppression may not require
the transactivation capacity of p53 (Crook et al., 1994).
Importantly, it has recently been demonstrated that p53-
dependent apoptosis of somatotropic progenitor cells in
response to X-rays occurs in the absence of new RNA or
protein synthesis (Caelles et al., 1994). Conversely, loss
of growth suppressor function has been reported in some
p53 mutants which retain transcriptional activity (Zhang
et al., 1994). However, discrepancies do exist in the
literature and other authors find a very strong correlation
between transcriptionally active p53 and the ability of the
protein to suppress cell growth (e.g. Reed et al., 1993;
Pietenpol, 1994).
It has long been known that p53 can directly prevent
viral DNA synthesis by binding to and inactivating SV40
large T antigen (Lane and Crawford, 1979; Linzer and
Levine, 1979; Braithwaite et al., 1987; Wang et al., 1989;
Friedman et al., 1990) and p53 may compete with DNA
polymerase ax for binding to T antigen (Gannon and Lane,
1987). In DNA synthesis, T antigen functions as a helicase
to promote strand unwinding at the replication fork, and
p53 down-regulates this activity (Sturzbecher et al., 1988).
Therefore, it is conceivable that p53 interacts with cellular
proteins analogous to T antigen to prevent DNA replication
under unfavourable conditions, e.g. when damage to the
genome has been sustained. Following from this predic-
tion, various cellular proteins have been isolated that
compete with T antigen for p53 binding (Takimoto et al.,
1994) and that bind to a conformation-sensitive domain
of p53 (Maxwell and Roth, 1993; Iwabuchi et al., 1994).
More specifically, Dutta et al. (1993) have shown that
p53 interacts with the single-strand DNA binding protein
RP-A and that this association is sufficient to prevent
replication of viral DNA in a soluble in vitro system.
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However, it has been noted that mutants of p53 that no
longer arrest cell growth are still able to bind to RP-A,
and p53 might even enhance DNA replication, since the
transactivation domain of p53 fused to the DNA binding
region of Gal4 has been found to stimulate polyomavirus
or bovine papillomavirus DNA replication (He et al.,
1993; Li and Botchan, 1993). On the basis of these
observations, a model has been proposed where p53 binds
to cellular origins of replication and there may interact
with key replication proteins to block entry into S phase
or to direct S phase cells into apoptosis (Pietenpol and
Vogelstein, 1993). In addition, by virtue of its non-specific
nucleic acid binding properties, p53 has been found to
promote re-annealing ofDNA and RNA strands (Oberosler
et al., 1993; Brain and Jenkins, 1994), thus acting as an
anti-helicase, a property that would suggest the protein
should be active in preventing nuclear DNA synthesis.
However, an effect on nuclear, as opposed to viral,
DNA replication has not previously been experimentally
addressed, possibly because of the confusion between the
indirect, transcriptional contribution and a direct role.
In this paper we have therefore investigated whether
p53 has a direct role in arresting nuclear DNA replication.
In order to distinguish between a transcriptional role and
a more direct effect of p53 in causing growth arrest, we
examined the effect of purified p53 on the replication of
DNA in cell-free extracts of Xenopus eggs. Such extracts
support the initiation and elongation stages of DNA
replication in a manner that is regulated temporally (Blow
and Watson, 1987; Hutchison et al., 1987) and spatially
(Hutchison and Kill, 1989; Mills, et al., 1989; Cox and
Laskey, 1991), but they do not support transcription
(Bachvarova and Davidson, 1966).
Activity of mammalian p53 in vivo is regulated by a
variety of mechanisms, including protein degradation,
phosphorylation, redox, oligomerization and allosteric
modification of the C-terminus (Hupp et al., 1992, 1993;
Hupp and Lane, 1994). An alternately spliced form of
murine p53 (p53,s) has been described in normal (Han
and Kulesz-Martin, 1992) and transformed cells (Arai
et al., 1986; Milner et al., 1993). This protein, which
represents 25-33% of total cellular p53, is preferentially
expressed in G2 of the cell cycle under normal conditions,
but becomes preferentially expressed in GI on treatment
with actinomycin D (Kulesz-Martin et al., 1994), both
being occasions when DNA synthesis must be suppressed.
P53as is nine amino acids shorter at the C-terminus than
the major p53 and therefore would not be subject to the
same allosteric modifications as the major p53. In this
study, therefore, two different forms of p53 were compared
for activity; full-length wild type p53 (wtpS3) and a 30
amino acid C-terminal truncation (p53A30). wtp53 has
latent sequence-specific DNA binding capacity that can
be activated, for example by phosphorylation by casein
kinase II at the C-terminus (Hupp et al., 1993; Meek
et al., 1990), whereas pS3A30 is constitutively active for
DNA binding (Hupp et al., 1992). Correlation between
the new structural models of p53 (Cho et al., 1994; Clore
et al., 1994) and accumulated mutational data (Hollstein
et al., 1992) suggests that DNA binding is critical for the
tumour suppressor function (Friend, 1994). It is conceiv-
able that effective mechanisms to inactivate the DNA
binding or growth suppressing properties of p53 exist in
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Fig. 1. wtp53 and p53A30 structure. Full-length human p53 consists of
393 amino acids. Within the C-terminus are found nuclear localization
sequences (NLS), an oligomerization domain (hatched box, amino
acids 320-360), a basic region (b) and sites which can be
phosphorylated by the cell cycle kinase cdk2 and casein kinase II
(CKII). In p53A30, the C-terminal 30 amino acids have been deleted,
such that one NLS and the oligomerization domain are conserved, but
the CKII phosphorylation site is lost. This protein is constitutively
active for sequence-specific DNA binding (Hupp et al., 1992).
the activated Xenopus egg extract in order to permit the
very rapid synchronous cell cycles of alternating S and
M phases of early amphibian embryos. Therefore, it was
important to employ these two forms of the protein, one
(wtp53) that retains the C-terminus regulatory domain and
is susceptible to putative regulatory factors in the Xenopus
egg extract and the other, p53A30, that should be relatively
resistant to allosteric modulation. Here we show that
human p53A30 inhibits nuclear DNA replication in a
reversible, concentration-dependent manner, while full-
length p53 with inducible DNA binding activity has no
effect on nuclear DNA replication. The inhibitory activity
of p53A30 is found to be ablated by oxidation of the
protein. Importantly, this is the first demonstration that
activated p53 can inhibit true eukaryotic nuclear, rather
than viral, DNA replication in the absence of transcription.
Results
p53A30 blocks nuclear DNA replication
To determine whether p53 affected nuclear DNA replica-
tion, purified recombinant human protein, either full-
length wild-type (wt) p53 or p53A30 lacking the C-terminal
30 amino acids (Figure 1), was added to Xenopus egg
extract containing sperm chromatin, and DNA synthesis
was analysed by incorporation of [a-32P]dATP. Figure 2A
shows that replication of sperm nuclei was significantly
inhibited by 20 ng/,ul p53A30 and completely abolished
at 40 ng/,l, whereas full-length wtp53 that had been
purified under identical conditions did not appreciably
affect the levels of replication of sperm nuclei. A mutant
form of full-length p53 (His273) that lacks growth sup-
pressing activity in vivo and and DNA binding capacity
in vitro (Halazonetis et al., 1993) does not affect replication
of sperm nuclei in this system (data not shown). Immuno-
blots of these samples probed with the N-terminal anti-
human p53 antibody DOl (Figure 2B) show that wtp53
and p53A30 were both equally stable during the course
of the experiment. In contrast, wtp53 and p53A30 both
inhibited replication of SV40 DNA in a HeLa cell extract
(Figure 2C), demonstrating that the wtp53 is functionally
active (Wang et al., 1989; Friedman et al., 1990).
a-amanitin added to the replication extract neither
decreased nuclear DNA synthesis in the presence of wtp53
nor did it relieve the inhibition imposed by p53A30 (data
not shown), verifying that p53A30 blocks nuclear DNA
replication in the absence of transcription.
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Fig. 2. p53A30 but not full-length wtp53 inhibits nuclear DNA
replication. (A) Inhibition of nuclear DNA replication by p53A30
(closed circles) is concentration-dependent, whereas wtp53 (open
circles) does not prevent replication. (B) Immunoblot probed with anti-
human-p53 monoclonal antibody DOI following 3 h incubation of
wtp53 or p53A30 in Xenopus egg extract [samples taken from the
experiment shown in (A)], demonstrating that full-length and truncated
p53 are equally stable in this system. (C) Both wtp53 (open circles)
and p53A30 (closed circles) inhibit SV40 T antigen-dependent
replication of circular plasmid DNA containing the SV40 origin of
replication, as previously reported (Friedman et al., 1990; Wang et al.,
1989).
p53A30 inhibits initiation of DNA replication
Is the replication block by p53A30 exerted at the level of
initiation or elongation during DNA synthesis? p53A30
was added to egg extract at different times during replica-
tion and the amount of DNA synthesis measured at the
time of p53 addition (filled columns) or after a total of
3 h incubation (hatched columns). From Figure 3A it is
apparent that the inhibitory effects of p53A30 are greatest
if the protein is added within the first 15 min of incubation.
It is during this period that sperm chromatin decondenses
and is assembled into intact nuclei, and that initiation of
DNA replication takes place (Blow and Laskey, 1986;
Blow and Watson, 1987). Immunofluorescence microscopy
analysis (data not shown) revealed that nuclei were
assembled normally in the presence of either wtp53 or
p53A30 and that the proteins became localized within
nuclei. Therefore, the observed inhibition was not due to
a failure in nuclear assembly.
A gradual decrease in inhibitory activity was noted with
increasing time of addition of p53A30 (Figure 3A) until,
at 120 min, there was virtually no effect, probably because
replication is complete and only a single round of DNA
synthesis takes place in these extracts (Blow and Laskey,
1986, 1988). Since addition of p53A30 at times up to 60
min also resulted in some decrease in overall levels of
DNA synthesis achieved, these data suggest that p53A30
can arrest DNA synthesis even when replication forks are
actively elongating. Although we cannot rule out the
possibility that initiation is not synchronous and is there-
fore prevented by p53A30 in late replicating nuclei, this
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Fig. 3. p53A30 inhibits initiation of nuclear DNA replication.
(A) Time course of p53A30 addition to Xenopus egg extract, showing
that inhibition of sperm nuclear replication is maximal when p53A30
is added at or before the time of nuclear envelope assembly (Blow and
Laskey, 1986; Blow and Watson, 1987). Hatched columns show the
final level of DNA replication after a total 3 h incubation and filled
columns show the amount of replication that had taken place before
p53A30 was added to the extract at 'time'. (B) p53A30 reduces
replication of Xenopus sperm nuclei (sn+p53) at least 5-fold from the
levels observed without added p53A30 (sn), but does not prevent the
formation of a second strand of DNA on a single-stranded M13 DNA
template (compare M13+p53 with M13 alone).
explanation is less likely, since replication in this system
is known to occur so rapidly that almost all replication
forks must initiate synchronously (Blow and Watson,
1987; Mills et al., 1989). However, these data show
that the majority of inhibition occurs at or shortly after
initiation.
To further define the activity of p53A30, the synthesis
of DNA on a single-stranded M13 DNA template was
compared with that of sperm chromatin in the presence
and absence of p53A30 (Figure 3B). While replication of
sperm nuclei was strongly inhibited, the second-strand
synthesis reaction on M13 was not greatly affected by
p53A30. This aphidicolin-sensitive reaction has been
likened to lagging strand DNA synthesis (Mechali and
Harland, 1982) and can occur in the absence of nuclear
structure (Cox and Leno, 1990). Thus p53A30 does not
interfere directly with polymerase a/8/£ activity in this
system nor can it act simply by coating DNA, but it
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Fig. 4. Oxidation of p53A30 abolishes inhibitory activity. Oxidized
p53A30 (p53A30+NEM+DTT) that has lost DNA binding activity
(Hupp et fl., 1993) does not inhibit nuclear DNA replication when
added to the Xenopus egg extract, whereas reduced p53A3O completely
inhibits nuclear replication under the same conditions. The 'buffer'
control contains the same volume of EBb as that added to the extract
in the p53A30 sample.
does inhibit the synthesis of DNA at replication forks
within nuclei.
Oxidation of p53A30 inactivates its inhibitory
activity
Since p53A30 prevents nuclear DNA replication and full-
length wtp53 does not, it was intriguing to determine
whether the difference between these two forms of p53
lay in their different abilities to bind DNA. In the first
instance, therefore, the DNA binding activity of p53A30
was ablated. Oxidation of p53 by agents such as
N-ethylmaleimide (NEM) has been found to prevent
p53A30 from binding to DNA (Hupp et al., 1993).
Therefore, we treated p53A30 with NEM, then quenched
NEM activity using dithiothreitol (DTT) before addition
to egg extract. Figure 4 shows that p53A30 oxidized by
NEM/DTT treatment fails to inhibit replication, unlike
untreated (reduced) p53A30. Addition of the same concen-
trations of NEM/DTT alone to the Xeniopus egg extract
had no significant effect on the level of DNA replication
(data not shown). Incidentally, this result strongly suggests
that it is p53A30 itself, rather than a non-specific co-
purifying contaminant, that is exerting an effect on DNA
synthesis. Therefore, the ability of p53A30 to block DNA
replication in litro is dependant on the protein existing in
a reduced state and this correlates with its ability to
bind DNA sequence-specifically. Hence, DNA binding by
p53A30 is necessary for its ability to inhibit nuclear DNA
replication.
Activation of wtp53 for DNA binding does not lead
to inhibition of DNA replication
The p53A30 block to replication observed above may be
due to the protein's enhanced double-strand DNA binding
affinity compared with wtp53 (Hupp et al., 1992). Full-
length human p53 can be induced to bind DNA sequence-
specifically with high affinity by incubating with an anti-
C-terminal monoclonal antibody, PAb421 (Hupp et al.,
1992). Since DNA binding is necessary for inhibition of
replication by p53, we addressed the question of whether
such binding is sufficient to impose a block on DNA
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Fig. 5. Activation of wt p53 for DNA binding does not inhibit DNA
replication. (A) wtp53 (open circles) is not activated for inhibition of
nuclear replication by treatment with equimiolar amounts of the anti-
p53 (C-terminus) monoclonal antibody PAb421 (crosses), even though
this treatment i.n vitro enhances its sequence-specific DNA binding
capacity (Hupp et al., 1992), whereas the constitutively activated form,
p53A30), does block replication under identical conditions (closed
circles). PAb421 alone added to replication mixes had no effect on the
level of DNA synthesis (data not shown). (B) The p53 DNA binding
consensus sequence polygrip (PG) does not competitively relieve
inhibition of nuclear replication and may even lead to further
inhibition when co-added with p53A30. Control samples included
addition of PG DNA alone or EBb. All added volumes were the same
so as to eliminate any dilution effects.
replication. We therefore compared replication of sperm
nuclei in the presence of p53A30, wtp53 or wtp53 com-
plexed with PAb421, to see if DNA binding was solely
responsible for the inhibition of replication. Figure 5A
clearly demonstrates that wtp53-421 behaved in the same
way as wtp53 alone and did not inhibit replication of
sperm nuclei ini vitro, whereas p53A30 again showed
concentration-dependent inhibition of replication. Hence,
DNA binding by p53 is necessary, but not sufficient, for
inhibition of nuclear DNA replication.
We further investigated whether DNA binding was the
sole mechanism for the observed replication block, by
competition analysis using an oligonucleotide containing
the p53-specific DNA binding sequence PG (El-Deiry
et al., 1992). The data in Figure 5B show that co-
incubation of p53A30 and PG DNA did not relieve the
replication block. These results suggest that this block
may require p53 to bind its target DNA sequence, but that
additional mechanisms, such as protein-protein inter-
actions between p53 (bound to DNA) and replication
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Human p53 blocks nuclear DNA replication
proteins, might enhance the inhibitory effects of p53 on
DNA replication.
Discussion
This paper aimed to distinguish between transcriptional
and replication roles of p53 by examining the effects of
purified human p53 on nuclear DNA replication in a cell-
free replication system derived from activated Xenopus
eggs (Blow and Laskey, 1986) that does not support
transcription (Bachvarova and Davidson, 1966). This
system is exciting in that it exploits a natural developmental
phenomenon that allows experimental dissociation of these
two fundamental processes without resorting to damaging,
artefact-inducing drugs. It is also the only cell-free system
to date known to support temporally and spatially regulated
replication of eukaryotic nuclei (Blow and Laskey, 1986,
1988; Blow and Watson, 1987; Hutchison et al., 1987;
Mills et al., 1989; Cox and Laskey, 1991), as opposed to
viral DNA synthesis in soluble systems. The early Xenopus
embryo undergoes 12 synchronous and very rapidly
alternating S and M phase cell cycles without intervening
G phases (Laskey, 1985), so it is likely that any endogenous
damage check-point controls, such as that mediated by
p53, remain latent until after the mid-blastula transition
(MBT), when the cell cycle lengthens and incorporates G
phases (Newport and Kirschner, 1982). Xenopus laevis is
tetraploid and has two genes for p53 (Soussi et al., 1987;
Hoever et al., 1994). Although maternal stockpiles of p53
mRNA and protein are present in early development
(Tchang et al., 1993; Cox et al., 1994; Hoever et al.,
1994), it is probable that mechanisms exist in the rapidly
dividing pre-MBT embryo to inactivate growth suppressor
proteins such as p53, perhaps by dephosphorylation (Hupp
et al., 1993). By using the truncated form of human p53,
which lacks the C-terminal casein kinase II phosphoryla-
tion site (Meek et al., 1990), we have been able to
overcome these putative inactivation mechanisms.
In this paper we observe that a C-terminal truncated
form of p53, p53A30, which lacks part of the negative
regulation domain and can bind DNA constitutively,
inhibits nuclear DNA synthesis in a concentration-
dependent manner in the Xenopus egg extract, whereas
full-length wtp53 has no effect on nuclear DNA replica-
tion. The two forms of p53 were found to be equally
stable during the course of these experiments, so the
difference in replication effect was not due to differential
degradation of wtp53 over p53A30. Both p53A30 and
wtp53 inhibit synthesis of SV40 DNA in extracts of
human HeLa cells. SV40 viral DNA replication in HeLa
cell extract requires the activity of the essential viral
replication protein, large T antigen. wtp53 is known to
bind to T antigen and block its replication activities (Wang
et al., 1989; Friedman et al., 1990) and we have shown
that p53A30 equally interacts with T antigen (L.S.Cox,
unpublished observations) to prevent viral DNA synthesis.
The two experimental replication systems used in this
paper therefore differ in that nuclear DNA replication in
the Xenopus system uses normal eukaryotic synthetic
machinery, while SV40 DNA synthesis depends on T
antigen. This difference may account for the ability of
wtp53 to inhibit SV40 but not nuclear DNA synthesis, as
shown here. The concentration of p53A30 required to block
nuclear DNA replication is suggestive of a stoichiometric
requirement for p53 in replication complexes; inhibition
of SV40 replication by p53 binding to and inactivating T
antigen requires very similar concentrations of p53. No
detectable transcription takes place in the Xenopus egg
extract, suggesting that the observed replication block
does not require the transcriptional activity of p53. The
absence of a transcriptional component to the replication
block was verified by using the RNA polymerase inhibiting
drug x-amanitin.
In human cells, full-length wtp53 is thought to exert
the detected cell cycle block in response to DNA damage
(Kasten et al., 1991, 1992; Lu and Lane, 1993), so what
is the relevance of inhibition by an artificially truncated
form of the protein? An alternately spliced form of p53,
which is nine amino acids shorter at the C-terminus, exists
at 25-33% of the major p53 species in normal and
transformed mouse cells (Han and Kulesz-Martin, 1992;
Kulesz-Martin et al., 1994), thus lacking the casein kinase
II phosphorylation sites and possibly also lacking other
allosteric regulation sites. This protein is preferentially
present at times when DNA replication does not take
place, i.e. during G2 of the normal cell cycle and in GI
when the DNA has been damaged by drug treatment
(Kulesz-Martin et al., 1994). It also appears probable that
on DNA damage, wtp53 may change in conformation
from a 'latent' form with weak affinity for DNA to an
'active' form that binds DNA more strongly (Hupp et al.,
1992; Lane, 1992), possibly by C-terminal modification,
such as phosphorylation (Hupp et al., 1993), alternative
multimerization or even by controlled cleavage of the
protein. By using p53A30, we have supplied an artificially
activated form of p53 that cannot be inactivated by growth
promoting factors in the egg extract. This form of p53
may reflect the activity of endogenous mammalian p53 in
cells harbouring damaged DNA.
p53A30 was found to block nuclear DNA replication
at an early stage, either at or soon after initiation, but it
does not prevent synthesis of a second strand of DNA on
a primed single-stranded M13 template. Therefore, p53
does not directly interfere with the DNA polymerases, and
it appears from our data that replication forks structurally
constrained within nuclei are the targets of p53 action. In
favour of the hypothesis that p53 prevents initiation or
early fork unwinding are the observations of Oberosler
et al. (1993) and Brain and Jenkins (1994) that p53 can
act to promote re-annealing of separated strands of DNA
and RNA. Additionally, p53 binds to RP-A (Dutta et al.,
1993) and so may promote destabilization of the single-
stranded regions at the replication fork and hence enhance
re-association of the strands.
DNA binding appears critical for the ability of p53 to
suppress growth (Friend, 1994), on the basis of structural
(Cho et al., 1994; Clore et al., 1994) and mutational
(Hollstein et al., 1991) analyses of p53. Here we show
that the ability of p53A30 to block DNA replication
correlates with its DNA binding capacity, since oxidation
leads to loss of both activities. This result may be taken
to imply that the inhibition of DNA replication is exerted
by p53 imposing a steric block to passage of replication
forks. Therefore, it is possible that by binding to DNA,
either in cis (on replicating DNA) or in trans (by associa-
tion with its consensus sites in other regions of the
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genome), p53 may be conformationally altered in such a
way as to act more efficiently as an anti-helicase or to
interact more strongly with proteins of the replication
complex. Interestingly, wtp53, which is usually activated
for DNA binding by incubation with the C-terminal
.antibody PAb 421, could not be activated to block DNA
synthesis, suggestive of steric effects of the bound antibody
that may prevent direct associations with replication
proteins.
It is probable that p53 acts on the cell cycle in multiple
ways to ensure that DNA replication is prevented on
genotoxic insult. First, by modulating transcription of
regulatory genes such as p21/WAF-1 (El-Deiry et al.,
1993; Gu et al., 1993; Harper et al., 1993; Sefrano et al.,
1993; Xiong et al., 1993), the activity of cyclin-cdk
kinase complexes is regulated and the cell cycle arrested
either in GI, at the G1/S border or in S phase, via p21-
mediated inhibition of cyclinE-cdk2, cyclinA-cdk2 or
cyclin A-cdc2 respectively (Dulic et al., 1994). If cells
manage to progress into S phase in the presence of
damage, then p21 induced by p53 can bind to and
inactivate the essential replication protein PCNA (Flores-
Rozas et al., 1994; Waga et al., 1994; Warbrick et al.,
1995). In addition to these transcriptional mechanisms,
the data we present here strongly suggest that p53, when
activated in vivo, can itself block DNA replication. By a
combination of these three mechanisms, the cell should
ensure that DNA replication cannot proceed until damage
has been repaired or that the cell undergoes apoptosis
rather that attempting to divide. In support of our results
are the findings of Caelles et al. (1994), that show no
requirement for either new RNA or protein synthesis for
p53-dependent apoptosis.
In conclusion, in this paper we have managed to
dissociate the putative roles of p53 in transcription and
DNA replication by using a replication system in which
measurable transcription does not take place and our
results show that an additional mechanism for growth
suppression by p53 may exist via a direct block on
eukaryotic nuclear DNA replication.
Materials and methods
p53 expression and purification
Human p53 was expressed in Escherichia coli (Midgley et al., 1992) or
insect Sf9 cells infected with baculovirus containing cDNA for wtpS3
or p53A30 (Hupp et al., 1992). After biochemical purification on
heparin-Sepharose and gel filtration, the proteins were microdialysed
into EBb buffer (50 mM KC1, 50 mM HEPES-KOH, pH 7.4, 5 mM
MgCl2, 2 mM P-mercaptoethanol, 10% glycerol, 0.1% Triton X-100).
There was no appreciable difference in the activity of p53 proteins from
bacterial or baculovirus sources (data not shown).
Replication reactions
Xenopus egg extract was prepared essentially as described by Blow and
Laskey (1986). Replication reactions were supplemented with an energy
regenerating system (150 gtg/ml creatine phosphokinase, 60 mM phospho-
creatine), 100 gg/ml cycloheximide and 800 Ci/mmol [cz-32P]dATP
(Amersham). Demembranated Xenopus sperm nuclei were prepared
according to the method of Gurdon (1976). Single-stranded M13 DNA
was prepared by standard methods (Sambrook et al., 1989), RNase
treated and purified by centrifugation on caesium chloride gradients.
DNA templates were used at a final concentration of 5 ng/,l, and
purified wtpS3 or p53A30 was added to various final concentrations up
to 40 ng/pI. The same volume of EBb was added to negative control
samples (without p53) as the volume of p53 in EBb added to the
experimental samples, to control for dilution and buffer effects. Where
appropriate, p53A30 was oxidized by treating with 5 mM NEM and
then 5 mM DTT was added to quench the reaction. Reactions were
carried out at 23°C for 3 h and incorporation of label determined by
trichloroacetic acid precipitation followed by scintillation counting. A
series of experiments using human p53 purified from baculovirus and
E.coli expression systems showed inhibition of nuclear DNA replication
at the same concentrations of p53 and representative examples are shown
in the figures. Error bars are not shown, since Xenopus egg extracts vary
from batch to batch in the absolute levels of DNA synthesis observed
(see Table I in Blow and Laskey, 1986). SV40 DNA replication reactions
were performed essentially as described in Wang et al. (1989), except
that total reaction volumes were 10 gl. Antibody PAb421 against the
C-terminus of p53 was purified on protein A-Sepharose and dialysed
into EBb before mixing at equimolar concentrations with wtp53 or direct
addition to the extract. PG DNA was prepared as previously described
(Hupp et al., 1992), but was not radioactively labelled. Where stated,
the transcriptional inhibitor a-amanitin was used at a final concentration
of S ,ug/ml.
Immunoblotting
Proteins were electrophoresed on 10% SDS - PAGE, transferred to
nitrocellulose and probed with undiluted tissue culture supernatant of
the monoclonal antibody DOI (Vojtesek et al., 1992). Secondary
horseradish peroxidase-conjugated rabbit anti-mouse antibody was used
at 1:1000 dilution and visualized by the ECL technique.
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